

## Product Information

### FIBROBLAST GROWTH FACTOR RECEPTOR 3 $\alpha$ (IIIc)/Fc Chimera

Human, Recombinant  
Expressed in mouse NSO cells

Product Number **F 9924**

#### Product Description

Recombinant Fibroblast Growth Factor Receptor 3 $\alpha$  (IIIc)/Fc Chimera is produced from a DNA sequence encoding the extracellular domain of human FGF R3 $\alpha$  (IIIc) protein and fused to the carboxy-terminal Fc region of human IgG1 by a polypeptide linker.<sup>1</sup> Mature human FGF R2 $\alpha$  (IIIc)/Fc is a disulfide-linked homodimeric protein. Based on amino-terminal sequencing, the mature protein has Ala 44 at the N-terminus. The reduced monomer has a calculated molecular mass of approximately 64 kDa. As a result of glycosylation, the recombinant protein migrates to approximately 100 to 110 kDa in SDS-PAGE.

Fibroblast growth factors (FGFs) are members of a large family of structurally related polypeptides (17 kDa to 38 kDa) that exert biological activities toward cells of mesenchymal, neuronal, and epithelial origin.<sup>2,3</sup> All members of the FGF superfamily have two conserved cysteine residues and a conserved 120 amino acid core region that contains six identical, interspersed amino acids.<sup>4,5,6</sup> All FGFs share 30 % to 50 % amino acid sequence identity. FGFs are involved in normal development, wound healing and repair, angiogenesis, a variety of neurotrophic activities. They are also involved in hematopoiesis as well as in tissue remodeling and maintenance. FGFs are potent physiological regulators of growth and differentiation for a variety of cells of mesodermal, ectodermal, and endodermal origin. They have been implicated in pathological conditions such as tumorigenesis and metastasis. To date, the FGF family consists of 23 members designated FGF-1 through FGF-23.<sup>6</sup>

Four distinct tyrosine kinase FGF receptors (FGFRs) from four separate genes have been identified: FGFR-1 (flg, cek-1), FGFR-2 (bek, cek-3), FGFR-3 (cek-2), and FGFR-4.<sup>7,8</sup> Multiple additional variants (isoforms) arising from alternative splicing have also been reported.<sup>8</sup> Ligand binding specificity, signal transduction, and membrane attachment may be modified by alternative splicings.

FGF Receptors are members of a family of type I transmembrane tyrosine kinases that mediate the biological activities of the FGFs by undergoing dimerization and autophosphorylation after ligand binding. The high affinity cell surface FGF receptors have an extracellular region containing three immunoglobulin-like domains, a transmembrane region, and a cytosolic tyrosine kinase domain activated by ligand binding. Alternative splicing of the mRNAs generates multiple forms of FGF R1, FGF R2, and FGF R3. FGF-R $\alpha$  and FGF-R $\beta$  are splicing isoforms of FGF-R.<sup>9</sup> FGF-R $\alpha$  has three Ig-like loops in the extracellular domain, while FGF-R $\beta$  has two Ig-like loops in the extracellular domain.<sup>9</sup> A major determinant of ligand binding specificity is alternative splicing in the C-terminus of Ig domain III of FGF R1-3. This splicing event is tissue-specific and is likely to regulate important signaling events across epithelial (b spliced form)/mesenchymal (c spliced form) boundaries.<sup>10</sup>

FGF R3 is widely expressed in many fetal and adult human and animal tissues. The FGF R3 expression profile correlates with its tissue specific expression at the mRNA level.<sup>11</sup> It is considered the only FGF receptor expressed in the organ of Corti of the rat cochlea.<sup>12</sup> Tissue cultured cells (such as COS-7) transfected with the full length FGF R3 cDNA display the expected membrane localization of the receptor. Interestingly, nuclear localization (nucleoli excluded) of FGF R3 attributable to a 110 kDa splice variant, has been reported for normal breast epithelial cells and breast cancer cells.<sup>13</sup> Deletions of chromosome 4p encompassing the FGF R3 gene cause the Wolf-Hirschhorn syndrome (growth failure, mental retardation, cardiac and bone malformations). Achondroplasia, an inherited disorder in which growth abnormality of bone or cartilage leads to skeletal maldevelopment and dwarfism, is associated with recurrent mutations of a single amino acid in the transmembrane domain of the FGF R3 protein.<sup>14</sup> Also, mutations in FGF R1, FGF R2, and FGF R3 are found in patients with birth defects involving craniosynostosis.

### Reagent

Recombinant Human Fibroblast Growth Factor Receptor 3 $\alpha$  (IIIc)/Fc Chimera is supplied as approximately 50  $\mu$ g of protein lyophilized from a 0.2  $\mu$ m filtered solution in phosphate buffered saline (PBS).

### Preparation Instructions

Reconstitute the contents of the vial using sterile phosphate buffered saline (PBS) containing at least 0.1% human serum albumin or bovine serum albumin. Prepare a stock solution of no less than 50  $\mu$ g/ml.

### Storage/Stability

Store at -20 °C. Upon reconstitution, store at 2 °C to 8 °C for one month. For extended storage, freeze in working aliquots. Repeated freezing and thawing is not recommended. Do not store in a frost-free freezer.

### Product Profile

Recombinant Human Fibroblast Growth Factor Receptor 3 $\alpha$  (IIIc)/Fc Chimera is measured by its ability to inhibit human FGF acidic-dependent proliferation of NR6 mouse fibroblasts.

The ED<sub>50</sub> for this effect is typically 2 to 6 ng/ml.

The ED<sub>50</sub> is defined as the effective concentration of growth factor that elicits a 50 % increase in cell growth in a cell based bioassay.

Purity: > 90 % as determined by SDS-Page, visualized by silver stain.

Endotoxin level is < 0.15 ng/ $\mu$ g protein as determined by the LAL (Limulus amebocyte lysate) method.

### References

1. Katoh, O., et al., *Cancer Res.*, **53**, 1136 (1993).
2. Givol, D., and Yaron, A., *FASEB. J.*, **6**, 3362 (1992).
3. Baird, A., et al., *Curr. Opin. Neurobiol.*, **4**, 78 (1994).
4. Fernig, F.G., and Gallagher, J.T., *Prog. Growth Factor Res.*, **5**, 353 (1994).
5. Kirkoshi, J., et al., *Biochem. Biophys. Res. Commun.*, **274**, 337 (2000).
6. Nishimura, T., et al., *Biochem. Biophys. Acta.*, **1492**, 203 (2000).
7. Bernard, O., and Matthew, P., *Guidebook to Cytokines and Their Receptors*, Oxford Press (New York, NY: 1994).
8. Galzie, Z., et al., *Biochem. Cell Biol.*, **75**, 669 (1997).
9. Hou, J., et al., *J. Biol. Chem.*, **267**, 17804-17808 (1992).
10. Chellaiah, A., et al., *J. Biol. Chem.*, **274**, 34785-34794 (1999).
11. Hughes, S.E., et al., *J. Histochem. Cytochem.*, **45**, 1005 (1997).
12. Pirvola, V., et al., *Proc. Natl. Acad. Sci. USA*, **92**, 9269 (1995).
13. Johnston, C.L., et al., *J. Biol. Chem.*, **270**, 30643 (1995).
14. Rousseau, F., et al., *Nature*, **371**, 252 (1994).

KAA 05/01

Sigma brand products are sold through Sigma-Aldrich, Inc.

Sigma-Aldrich, Inc. warrants that its products conform to the information contained in this and other Sigma-Aldrich publications. Purchaser must determine the suitability of the product(s) for their particular use. Additional terms and conditions may apply. Please see reverse side of the invoice or packing slip.